ArticleJournal of thoracic disease2025
TTF-1 expression stratifies chemoimmunotherapy benefits in PD-L1-negative lung adenocarcinoma: a real-world biomarker validation.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The efficacy of immunotherapy in programmed death-ligand 1 (PD-L1)-negative advanced lung adenocarcinoma remains controversial, with responsive subgroups poorly characterized. This study aimed to identify predictive subgroups through thyroid transcription factor-1 (TTF-1) expression stratification. Methods: We retrospectively analyzed 253 consecutive PD-L1-negative advanced lung adenocarcinoma patients treated between January 2018 and January 2024. Outcomes of TTF-1-positive and TTF-1-negative patients receiving chemoimmunotherapy Results: In the overall cohort, chemoimmunotherapy improved median progression-free survival [PFS: 7.9 Conclusions: TTF-1 expression may be a useful predictive biomarker for chemoimmunotherapy benefit in PD-L1-negative lung adenocarcinoma, pending further validation. TTF-1-negative patients demonstrated improved survival with chemoimmunotherapy (especially taxane-based regimens) compared to chemotherapy alone, while TTF-1-positive patients showed no survival benefit from immunotherapy combinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.